| Dec'19 | Dec'18 | |||||
|---|---|---|---|---|---|---|
Collaboration revenue | ||||||
16,977 | 3,358 | |||||
Operating expenses: | ||||||
Research and development | ||||||
53,732 | 22,631 | |||||
General and administrative | ||||||
10,233 | 5,355 | |||||
Total operating expenses | ||||||
63,965 | 27,986 | |||||
Loss from operations | ||||||
-46,988 | -24,628 | |||||
Other income: | ||||||
Interest income, net | ||||||
4,666 | 871 | |||||
Other expense, net | ||||||
94 | 74 | |||||
Total other income, net | ||||||
4,572 | 797 | |||||
Loss before benefit from (provision for) income taxes | ||||||
-42,416 | -23,831 | |||||
Benefit from (provision for) income taxes | ||||||
912 | 0 | |||||
Net loss | ||||||
-43,328 | -23,831 | |||||
Net loss per share, basic and diluted | ||||||
-2.69 | -22.28 | |||||
Weighted average common shares outstanding, basic and diluted | ||||||
16,101 | 1,069 | |||||
Comprehensive loss: | ||||||
Net loss | ||||||
-43,328 | -23,831 | |||||
Other comprehensive income: | ||||||
Unrealized holding gains on marketable securities | ||||||
44 | - | |||||
Total other comprehensive income | ||||||
44 | - | |||||
Comprehensive loss | ||||||
-43,284 | -23,831 | |||||
AbbVie | ||||||
Collaboration revenue | ||||||
10,797 | 3,358 | |||||
Janssen | ||||||
Collaboration revenue | ||||||
6,180 | - | |||||